Bryn Mawr Trust Advisors LLC Makes New $484,000 Investment in Quest Diagnostics Incorporated $DGX

Bryn Mawr Trust Advisors LLC purchased a new stake in Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,283 shares of the medical research company’s stock, valued at approximately $484,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of DGX. Mill Capital Management LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at $343,000. Tema ETFs LLC boosted its stake in Quest Diagnostics by 10.6% during the second quarter. Tema ETFs LLC now owns 1,518 shares of the medical research company’s stock worth $322,000 after acquiring an additional 145 shares in the last quarter. Czech National Bank grew its holdings in Quest Diagnostics by 5.2% in the second quarter. Czech National Bank now owns 31,508 shares of the medical research company’s stock worth $6,678,000 after purchasing an additional 1,550 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in Quest Diagnostics by 7.7% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 14,000 shares of the medical research company’s stock worth $2,967,000 after purchasing an additional 1,000 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Quest Diagnostics by 39.1% in the second quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company’s stock valued at $3,265,000 after purchasing an additional 4,334 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Quest Diagnostics Trading Down 0.7%

NYSE:DGX opened at $234.48 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $240.13. The company has a market cap of $25.88 billion, a PE ratio of 24.89, a PEG ratio of 2.18 and a beta of 0.56. The firm has a 50-day moving average of $215.60 and a 200-day moving average of $203.18.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities research analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.

Quest Diagnostics News Summary

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Insider Activity at Quest Diagnostics

In related news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 19,747 shares of company stock valued at $3,947,088 over the last 90 days. Insiders own 0.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DGX shares. Evercore set a $225.00 price objective on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Robert W. Baird boosted their target price on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Argus set a $260.00 price target on Quest Diagnostics in a research note on Wednesday, July 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $245.00 price target on shares of Quest Diagnostics in a report on Thursday, July 23rd. Finally, Barclays raised their price objective on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $235.31.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.